— Special Deep-Dive Analysis · March 2026 —

Artelo Biosciences (NASDAQ: ARTL)

Three Platforms, One Molecule, A Pipeline Built to Last

Beyond the glaucoma headline — why ART27.13, ART26.12, and ART12.11 form a more compelling story than most biotech investors realize

Clinical Stage  ·  Endocannabinoid / Lipid-Signaling  ·  San Diego, CA

Section 00  —  Executive Summary

The Case for ARTL in One Paragraph

Most coverage of Artelo Biosciences has focused on the glaucoma announcement — a meaningful and capital-efficient pipeline expansion that is genuinely worth tracking. But investors who stop there are missing the larger thesis. Artelo has successfully advanced three separate compounds through human clinical trials, generated positive interim Phase 2 data, attracted academic partners across the UK and Ireland, earned European patent protection extending to 2041, received regulatory guidance from the UK's MHRA, and drawn unsolicited partnership inquiries from global pharmaceutical companies — all while operating with a lean structure that keeps burn focused on science rather than overhead.

This report goes deeper than the glaucoma headline. We examine all three pipeline assets, the regulatory tailwinds reshaping the cannabinoid therapeutic landscape, the intellectual property architecture that protects the franchise, and the strategic signals embedded in recent SEC filings and press releases.

Section 01  —  The Pipeline

Three Compounds, One Scientific Thesis

Artelo's pipeline is built around a single mechanistic conviction: that modulating lipid-signaling pathways — including the endocannabinoid system — can produce clinically meaningful therapeutic outcomes across multiple disease areas without the CNS liability that has historically limited cannabinoid-based drug development. That conviction is now backed by human data across all three programs.

ART27.13 — The Lead Asset With Multiple Shots on Goal

ART27.13 did not originate at Artelo. It was initially developed by AstraZeneca — a meaningful credential that speaks to the compound's pharmaceutical-grade pedigree. By the time Artelo licensed it, ART27.13 had already been evaluated in seven clinical studies involving more than 280 participants. Artelo's contribution has been to identify the therapeutic sweet spot: peripheral selectivity that delivers systemic metabolic benefit while sidestepping the CNS effects that made first-generation cannabinoids clinically impractical.

These are not modest improvements. In cancer anorexia cachexia — where there is no FDA-approved treatment — a 6.4% weight gain versus a 5.4% weight loss in the placebo arm represents a clinically meaningful signal. The Phase 2 data was presented at the 17th International Conference on Sarcopenia, Cachexia & Wasting Disorders by Professor Barry J.A. Laird of Edinburgh Cancer Centre — giving the data independent scientific credibility beyond the company's own disclosures.

The glaucoma expansion layered on top of this is not speculative pivoting. It is a second indication discovered organically through the mechanism: ART27.13's CB2 receptor activity offers both intraocular pressure modulation and neuroprotective properties that current glaucoma therapies don't address. The investigator-sponsored trial structure means Artelo advances this indication at zero direct cost to shareholders while retaining full data rights.

"This collaboration broadens ART27.13's therapeutic profile beyond cancer-related anorexia while preserving our internal focus on the lead indication."

— Gregory D. Gorgas, President & CEO, Artelo Biosciences

ART26.12 — The Hidden Gem in a $20 Billion Pain Category

If ART27.13 is the headline act, ART26.12 may be the most underappreciated asset in the portfolio. Artelo's FABP5 (Fatty Acid Binding Protein 5) inhibitor completed its first-in-human Phase 1 single-ascending-dose study in 2025 with results that de-risked the program substantially.

The human data showed no serious adverse events, a favorable safety profile across all dose levels tested up to 1,050 mg, predictable and linear pharmacokinetics, and dosing flexibility in both fed and fasted states. These are the precise attributes a pharmaceutical partner wants to see before committing capital to a Phase 2 collaboration.

In an osteoarthritis pain model, ART26.12 produced sustained analgesic effects without the development of tolerance — a crucial differentiator from opioids and a meaningful advantage over NSAIDs like naproxen, which it matched in efficacy. A separate publication showed antidepressant-like activity on par with sertraline (Zoloft®) with improved cognitive benefits in preclinical models.

The lead indication under an active FDA IND is chemotherapy-induced peripheral neuropathy — a condition affecting a substantial share of the cancer patient population, currently managed with a limited toolkit of off-label medications. Multiple ascending dose enrollment is being prepared for Q3 2026.

ART12.11 — A Proprietary CBD Reinvention with Regulatory Momentum

ART12.11 is Artelo's wholly owned CBD/tetramethylpyrazine cocrystal — a novel crystalline form of cannabidiol that has demonstrated improved pharmacokinetics and efficacy versus conventional CBD in nonclinical studies. The cocrystal format is not a marketing distinction; it is a chemistry distinction that produces measurably different bioavailability and stability profiles.

The compound received favorable UK MHRA regulatory guidance supporting streamlined Phase 1 development with potential accelerated pathways. First-in-human studies are planned for the first half of 2026. ART12.11 is protected by patents extending to 2038 and is positioned at the intersection of two significant tailwinds: the White House executive order expanding CBD research and the Medicare pilot program for CBD reimbursement announced in late 2025.

Section 02  —  Regulatory Environment

The Regulatory Environment Has Shifted in Artelo's Favor

The cannabinoid therapeutic space has long operated under a regulatory cloud that created genuine commercial uncertainty even for companies with compelling science. That cloud is lifting — and the timing benefits Artelo directly.

These three policy developments — the Presidential EO, the Medicare pilot, and the MHRA pathway — arrived within months of each other. For Artelo, they represent a convergence of regulatory tailwinds that the company was already positioned to capture through a pipeline designed specifically around peripheral selectivity and pharmaceutical-grade formulation.

Section 03  —  Market Opportunity

The Market Opportunity Matrix

Artelo's total addressable market cannot be evaluated through a single-indication lens. Each of its three programs operates in a distinct therapeutic category with large and growing patient populations.

The cancer anorexia cachexia opportunity deserves particular attention because it carries a differentiator that is rarely available in biotech: there is no FDA-approved pharmacological treatment for the condition. The 2020 ASCO guidelines recommend no specific pharmacological intervention as standard of care. ART27.13, if it completes Phase 2 with the signal strength suggested by interim data, would enter a market with no incumbent to displace.

Section 04  —  Intellectual Property

The Intellectual Property Fortress

Patent protection is the commercial runway that converts clinical success into durable value. Artelo's IP position provides meaningful long-dated protection across all three programs.

The ART27.13 European patent allowance through December 2041 is particularly significant for licensing discussions. A potential pharmaceutical partner evaluating a collaboration would find a compound with 15+ years of commercial patent life, positive Phase 2 human data, and a clean safety profile across 7 studies — the combination that routinely drives outlicensing conversations in mid-stage biotech deals.

Section 05  —  Partnership Signals

The Partnership Signals Investors Should Not Ignore

Among the most consequential disclosures in Artelo's Q3 2025 earnings update — one that received little investor attention — was the company's acknowledgment of unsolicited interest:

"Following positive Phase 2 results and coverage by UK and USA media outlets, Artelo has received multiple expressions of potential collaboration interest from global and regional pharmaceutical companies."

— Artelo Biosciences Q3 2025 Business Update

In the clinical-stage biotech world, unsolicited partnership inquiries at the Phase 2 stage are not routine events. They represent external validation from parties with their own development budgets and scientific advisory teams — parties who don't make preliminary outreach calls without having reviewed the data themselves.

These expressions of interest have not converted to announced deals, and there is no guarantee they will. But they establish that Artelo's science is attracting attention beyond the retail investor community — and that the pipeline's future may not depend solely on Artelo's own capital position to reach commercialization.

The IST model for the glaucoma study reflects the same dynamic: Professor Augusto Azuara-Blanco at Queen's University Belfast and the Northern Ireland Clinical Trials Unit did not agree to sponsor a trial of ART27.13 without scientific conviction in the mechanism. Academic institution partnerships and pharma collaboration inquiries, taken together, suggest that ART27.13's clinical credibility is resonating well beyond the company's own press releases.

Section 06  —  Catalyst Calendar

Key Milestones to Watch

The 12-to-24-month catalyst runway for Artelo is more active than its market capitalization currently reflects.

Section 07  —  Capital Strategy

A Capital-Efficient Strategy Built for the Stage

Artelo's management team has made a series of deliberate structural decisions that reflect a clear-eyed understanding of how to advance a multi-program biotech pipeline while preserving shareholder capital. The result is a company that is doing more with less — and doing it strategically.

The investigator-sponsored trial model, most visibly deployed for the glaucoma expansion, is the clearest expression of this philosophy. By partnering with Glaucoma UK, the HSC R&D Division, and Queen's University Belfast, Artelo advances a $16.3 billion market opportunity without spending a dollar of shareholder capital on study costs — while retaining full data rights and strategic control. This is not a compromise; it is a competitive advantage.

The company entered 2026 with a secured equity access facility of up to $25 million — expandable to $50 million — providing a meaningful capital bridge as clinical programs continue to mature and generate data. With seven employees and a 2025 operating structure that directed $5.4 million of its total spend directly into R&D, Artelo runs lean by design. The science consumes the capital, not the overhead.

The 1-for-3 reverse stock split completed in March 2026 further strengthens the company's market positioning, improving share price structure and marketability for a broadening investor audience as clinical catalysts approach across all three programs.

What distinguishes Artelo from the broader universe of early-stage biotech is the quality of the science advancing through this stage. Three programs with human data. A lead compound with 280+ clinical participants across seven studies. External institutions willing to co-fund and co-investigate. Global pharmaceutical companies making unsolicited contact. These are the markers of a pipeline that the scientific community is taking seriously — and they represent the foundation on which long-term value creation is built.

The Vanderbilt Report  —  Investment Thesis

Why Artelo Biosciences Warrants Continued Attention